Raymond James reiterates Outperform rating on Doximity stock at $75 target

Doximity Inc. (NYSE:DOCS) has significantly expanded its Doximity GPT functionality, integrating its recent Pathways acquisition to provide AI-optimized data for physicians, a move seen as accelerating its AI initiatives. This development follows strong Q1 FY26 financial results, with the company exceeding revenue and EPS expectations at $145.9 million and $0.36 respectively. Analysts, including Raymond James and BofA Securities, have maintained or raised price targets to $75, while Piper Sandler increased its target to $69, citing Doximity's AI advancements and substantial physician reach as key drivers for competitive advantage and increased user engagement.

Analysis

Doximity Inc. (DOCS) has demonstrated robust operational performance and strategic acceleration in its artificial intelligence initiatives. The company reported strong Q1 FY26 results, with revenue of $145.9 million and EPS of $0.36, decisively beating Wall Street estimates of $139.43 million and $0.30, respectively. This financial outperformance is complemented by impressive fundamentals, including 90% gross margins and a 79% stock return over the past year. Strategically, the company has rapidly expanded its Doximity GPT functionality by integrating its recent Pathways acquisition just six weeks post-closure. This enhancement provides AI-optimized clinical data to its network, which covers over 80% of U.S. physicians, at no cost, a move designed to deepen user engagement and solidify its competitive moat. Analyst sentiment is largely positive, with Raymond James reiterating its Outperform rating and $75 price target, and Piper Sandler raising its target to $69, both citing AI advancements as a key driver. BofA Securities also increased its price target to $75, though it maintains a Neutral rating, linking the adjustment to broader sector changes such as FDA reforms on pharmaceutical advertising.

Key Decisions for Investors

• The combination of a significant Q1 earnings beat, high gross margins, and accelerated AI product deployment reinforces a bullish thesis, validating the company's growth strategy and market leadership.
• Investors should monitor user engagement and app utilization metrics, as the success of the free, expanded Doximity GPT offering is a critical forward-looking indicator of the platform's network effect and long-term monetization potential.
• While multiple analysts have raised price targets to the $69-$75 range, the 'Neutral' rating from BofA Securities suggests that investors should weigh the company's strong operational momentum against its current valuation and potential sector-wide regulatory shifts.